Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submissio ...
PDF (261 KB)
Updated Clinical Results and New Translational Research Data for Daiichi Sankyo’s ADCs U3-1402 and ...
PDF (297 KB)
Daiichi Sankyo Files Declaratory Judgement Action Related to its Proprietary Antibody Drug Conjugat ...
PDF (132 KB)
ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung ...
PDF (184 KB)
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric ...
PDF (179 KB)
ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer
PDF (186 KB)
Daiichi Sankyo and Gustave Roussy Enter Innovative Research Collaboration for DXd ADCs DS-1062 and ...
PDF (167 KB)
ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastati ...
PDF (246 KB)
Daiichi Sankyo Launches ENHERTU® in Japan for Patients with HER2 Positive Unresectable or Metastati ...
PDF (256 KB)
Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with Sarah Can ...
PDF (139 KB)
Showing 1 - 10 of 34 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...